Ocrevus is a less expensive treatment option for relapsing multiple sclerosis than Rebif in the long-run, according to a cost-effectiveness analysis published in the Journal of Medical Economics.
In addition ... Read more
The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt. Researchers discussed the findings at the American Academy ... Read more
Clinical results presented at the recent Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meeting in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses ... Read more